367 related articles for article (PubMed ID: 9026477)
1. Marked increase in gastric acid secretory capacity after omeprazole treatment.
Waldum HL; Arnestad JS; Brenna E; Eide I; Syversen U; Sandvik AK
Gut; 1996 Nov; 39(5):649-53. PubMed ID: 9026477
[TBL] [Abstract][Full Text] [Related]
2. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy.
Sanduleanu S; De Bruïne A; Stridsberg M; Jonkers D; Biemond I; Hameeteman W; Lundqvist G; Stockbrügger RW
Eur J Clin Invest; 2001 Sep; 31(9):802-11. PubMed ID: 11589723
[TBL] [Abstract][Full Text] [Related]
3. Omeprazole: its influence on gastric acid secretion, gastrin and ECL cells.
Larsson H; Håkanson R; Mattsson H; Ryberg B; Sundler F; Carlsson E
Toxicol Pathol; 1988; 16(2):267-72. PubMed ID: 3187355
[TBL] [Abstract][Full Text] [Related]
4. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.
Sanduleanu S; Stridsberg M; Jonkers D; Hameeteman W; Biemond I; Lundqvist G; Lamers C; Stockbrügger RW
Aliment Pharmacol Ther; 1999 Feb; 13(2):145-53. PubMed ID: 10102943
[TBL] [Abstract][Full Text] [Related]
5. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion.
Fossmark R; Johnsen G; Johanessen E; Waldum HL
Aliment Pharmacol Ther; 2005 Jan; 21(2):149-54. PubMed ID: 15679764
[TBL] [Abstract][Full Text] [Related]
6. Changes in gastric ECL cells and parietal cells after long-term administration of high-dose omeprazole to patients with Barrett's esophagus.
Nishi T; Makuuchi H; Weinstein WM
Tokai J Exp Clin Med; 2005 Jul; 30(2):117-21. PubMed ID: 16146202
[TBL] [Abstract][Full Text] [Related]
7. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.
Boyce M; Dowen S; Turnbull G; van den Berg F; Zhao CM; Chen D; Black J
Br J Clin Pharmacol; 2015 May; 79(5):744-55. PubMed ID: 25335860
[TBL] [Abstract][Full Text] [Related]
8. A review of the effects of long-term acid inhibition in animals.
Carlsson E
Scand J Gastroenterol Suppl; 1989; 166():19-23. PubMed ID: 2574909
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome.
Hirschowitz BI; Mohnen J; Shaw S
Aliment Pharmacol Ther; 1996 Aug; 10(4):507-22. PubMed ID: 8853754
[TBL] [Abstract][Full Text] [Related]
10. Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients.
Qvigstad G; Arnestad JS; Brenna E; Waldum HL
Scand J Gastroenterol; 1998 Dec; 33(12):1244-8. PubMed ID: 9930386
[TBL] [Abstract][Full Text] [Related]
11. Review article: the use of gastric acid-inhibitory drugs--physiological and pathophysiological considerations.
Waldum HL; Brenna E; Kleveland PM; Sandvik AK; Syversen U
Aliment Pharmacol Ther; 1993 Dec; 7(6):589-96. PubMed ID: 7909240
[TBL] [Abstract][Full Text] [Related]
12. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.
Rindi G; Fiocca R; Morocutti A; Jacobs A; Miller N; Thjodleifsson B;
Eur J Gastroenterol Hepatol; 2005 May; 17(5):559-66. PubMed ID: 15827447
[TBL] [Abstract][Full Text] [Related]
13. Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats.
Larsson H; Carlsson E; Håkanson R; Mattsson H; Nilsson G; Seensalu R; Wallmark B; Sundler F
Gastroenterology; 1988 Dec; 95(6):1477-86. PubMed ID: 3181674
[TBL] [Abstract][Full Text] [Related]
14. Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole.
Hage E; Hendel L; Gustafsen J; Hendel J
Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):781-9. PubMed ID: 12811309
[TBL] [Abstract][Full Text] [Related]
15. Omeprazole and ranitidine, antisecretagogues with different modes of action, are equally effective in causing hyperplasia of enterochromaffin-like cells in rat stomach.
Ryberg B; Bishop AE; Bloom SR; Carlsson E; Håkanson R; Larsson H; Mattsson H; Polak JM; Sundler F
Regul Pept; 1989 May; 25(2):235-46. PubMed ID: 2756157
[TBL] [Abstract][Full Text] [Related]
16. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.
McTavish D; Buckley MM; Heel RC
Drugs; 1991 Jul; 42(1):138-70. PubMed ID: 1718683
[TBL] [Abstract][Full Text] [Related]
17. [Gastrin/CCK-B receptor antagonists for a novel antiulcer agent].
Miyata K; Nishida A; Honda K
Nihon Yakurigaku Zasshi; 1995 Sep; 106(3):171-80. PubMed ID: 8529962
[TBL] [Abstract][Full Text] [Related]
18. Gastric ECL-cell hyperplasia produces enhanced basal and stimulated gastric acid output but not gastric erosion formation in the rat.
LePard KJ; Mohammed JR; Stephens RL
Gen Pharmacol; 1997 Mar; 28(3):415-20. PubMed ID: 9068983
[TBL] [Abstract][Full Text] [Related]
19. Is hypergastrinaemia dangerous to man?
Creutzfeldt W; Lamberts R
Scand J Gastroenterol Suppl; 1991; 180():179-91. PubMed ID: 1675024
[TBL] [Abstract][Full Text] [Related]
20. Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole.
Betton GR; Dormer CS; Wells T; Pert P; Price CA; Buckley P
Toxicol Pathol; 1988; 16(2):288-98. PubMed ID: 2903544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
